Introduction {#s1}
============

Genetic mutation, copy number gain/loss and chromosomal rearrangement are major mechanisms of genome alteration that underlie cancer pathogenesis. Frequent alteration of a gene by one or more of these mechanisms represents *prima facie* evidence for its role as a *driver* -- a gene whose alterations are causative in cancer. As such, within the last decade, tremendous efforts have focused on the systematic, genome-wide surveys for these events in cancer. Interestingly, results from these analyses indicate that many tumors harbor alterations in only 1--2 known drivers, and \~15% of tumors lack alterations in even a single known driver ([@bib16]; [@bib11]). Since solid tumors arise due to oncogenic cooperation between alterations in multiple drivers ([@bib8]; [@bib12]), a significant number of cancer-relevant genes are currently being missed by genomic analyses because so many genes are ostensibly altered at frequencies below the threshold for driver detection ([@bib19]).

While it has been posited that unidentified drivers are difficult to identify because they are infrequently altered in cancer, it is equally plausible that additional mechanisms, beyond those regularly interrogated by current genomics platforms, may be responsible for generating driver alterations. In fact, as new mechanisms of alteration relevant to cancer are discovered, a number of \'infrequently altered\' genes are reclassified as frequently altered. For example, the discovery of promoter mutations in the gene encoding telomerase has resulted in the reclassification of *TERT* as a frequently altered melanoma driver ([@bib14]; [@bib13]). Therefore, identifying cancer-specific alterations generated by previously unappreciated mechanisms represents a fundamentally important prerequisite for driver gene identification.

Ni et al. previously identified several dozen candidate cancer driver genes from a forward genetics screen for tumorigenesis in mice ([@bib23]). Despite being functionally implicated in tumorigenesis, some of these candidate drivers were rarely mutated, amplified or deleted in human cancer. This incongruence led us to hypothesize that some of these candidate drivers may appear to be infrequently altered because their driver alterations may be caused by mechanisms that are not regularly interrogated. Here, we report that one of these candidate drivers, *MAGI3*, is indeed recurrently altered in breast cancer by premature cleavage and polyadenylation (pPA), a mechanism not widely appreciated for its involvement in cancer, and the resulting truncation of the *MAGI3* gene products functionally contributes to malignant transformation.

Results {#s2}
=======

A premature polyadenylation event generates a truncated MAGI3 protein in MDA-MB-231 breast cancer cells {#s2-1}
-------------------------------------------------------------------------------------------------------

Many mechanisms are involved in conveying genetic information from genes to their mRNA and protein products. When gone awry, any of these mechanisms could alter cancer-relevant genes or their gene products. To investigate our hypothesis that some candidate drivers may be altered by underlying mechanisms not widely thought to be involved cancer, we considered strategies capable of broadly capturing many types of alteration events. While there is no standard strategy for this purpose, we reasoned that changes in genetic information, in most cases, must ultimately manifest at the protein level in order to contribute to cancer. Thus, our strategy focused on identifying novel, unannotated protein products of a limited number of genes that we suspected to be involved in cancer due to their previous identification by a forward genetics screen for tumorigenesis in mice ([@bib23]). We focused specifically on products exhibiting detectable size differences from wild-type protein isoforms since these may be more likely to cause significant functional effects. Once such a product was identified, we would determine whether the altered protein is generated by a genetic mutation in the coding regions of the corresponding gene ([Figure 1A](#fig1){ref-type="fig"}). If not due to coding region genetic mutation, we would attempt to identify the alteration mechanism, establish recurrence for the specific alteration event in cancer and investigate its functional importance in malignant transformation.10.7554/eLife.14730.003Figure 1.Premature polyadenylation of *MAGI3* in the MDA-MB-231 breast cancer cell line causes the expression of a truncated MAGI3 protein.(**A**) Strategy for identifying protein products altered by previously overlooked mechanisms. Protein products of previously identified candidate driver genes ([@bib23]) were screened by immunoblotting. Altered products were identified by electrophoretic mobility shift and confirmed by affinity purification-mass spectrometry (AP-MS). Exons of corresponding genes were sequenced. Genes not affected by coding-region DNA mutations were analyzed by 3′ RACE and sequencing to identify the nature of the altered product and the associated mechanism of alteration. Alteration events caused by mechanisms not widely appreciated in cancer were subsequently investigated for tumor-specific recurrence and functional relevance. (**B**) Immunoblot of *MAGI3* gene products in the screening panel of human breast cell lines. Non-transformed (green) and transformed (violet) cell lines are indicated. A truncated MAGI3 protein (indicated by red asterisks) is expressed in MDA-MB-231 cells. Immunoblot of β-actin is included to show loading. Approximate molecular mass markers are indicated in kDa. (**C**) Immunoblots of *MAGI3* gene products and β-actin levels in MDA-MB-231 cells transduced with the indicated shRNA constructs. The relative levels of full-length and truncated MAGI3 proteins following RNAi-mediated depletion are normalized to β-actin levels. The ratios of full-length to truncated MAGI3 (FL:truncated) are also quantified. (**D**) Immunoblot of *MAGI3* gene products in the indicated non-transformed cell lines (green) and MDA-MB-231 breast cancer cell line (violet). Immunoblot of β-actin is included to show loading. Approximate molecular mass markers are indicated in kDa. (**E**) Diagrams of the full-length MAGI3 protein isoforms α and β. Both full-length isoforms possess the indicated arrangement of 6 PDZ domains (dark grey), 2 WW domains (light grey) and a catalytically inactive GK domain with homology to the yeast guanylate kinase (black). In addition, isoform α has an extended C-terminal sequence with no known function. (**F**) Immunoblot for three MAGI3 protein isoforms immunoprecipitated from MDA-MB-231 cell lysate. The gel slice containing the smallest, truncated MAGI3 protein was analyzed by mass spectrometry, and peptides were mapped exclusively to the N-terminal half of the protein. Approximate molecular mass markers are indicated in kDa. (**G**) Detection of full-length and truncated *MAGI3* mRNA isoforms by 3′ RACE. Products from two independent nested 3′ RACE reactions performed on MDA-MB-231 RNA were separated by agarose gel electrophoresis. Truncated and full-length *MAGI3* transcripts are indicated. Diagrams show regions targeted for amplification and locations of primary (black) and nested (green/red) primers used for 3′ RACE. (**H**) Diagram of the truncated and prematurely polyadenylated *MAGI3* mRNA (*MAGI3^pPA^*) generated from the *MAGI3* gene locus despite the absence of genetic mutations within the gene. *Green box:* 3′ RACE sequencing results of *MAGI3^pPA^* show premature cleavage and polyadenylation (shaded yellow) following a cryptic PAS (outlined in red) in intron 10. The corresponding intron 10 genomic sequence is shown above in black. *Violet box:* Upstream of the pPA event, 3′ RACE sequencing results show a short extension of the open-reading frame into intron 10. The corresponding exon 10 and intron 10 genomic sequence is shown above in black, with the intact U1 snRNA binding site (GGTAAG) underlined in black. Intron 10 is shaded yellow. A stop codon (red underscore) occurs 6 nt following the exon-intron junction. Encoded amino acid sequence is shown in black above the nucleotide sequence (wild-type MAGI3, upper line; MAGI3^pPA^, lower line).**DOI:** [http://dx.doi.org/10.7554/eLife.14730.003](10.7554/eLife.14730.003)10.7554/eLife.14730.004Figure 1---figure supplement 1.Sequencing chromatograms of MDA-MB-231 genomic DNA focusing on *MAGI3* exon 10, intron 10 and exon 11.Sequencing traces for *MAGI3* exon 10, intron 10 and exon 11 are shown, with major cis-acting sequence features responsible for proper splicing and repression of premature polyadenylation annotated: splice junctions, U1 snRNA binding site and U-rich elements (URE). The location of the cryptic PAS is also indicated. No mutations were detected in these sequences.**DOI:** [http://dx.doi.org/10.7554/eLife.14730.004](10.7554/eLife.14730.004)10.7554/eLife.14730.005Figure 1---figure supplement 2.Sequencing chromatograms of the *MAGI3^pPA ^*product from exon 10 to the poly(A) tail downstream of the cryptic PAS in intron 10.Sequencing traces for the *MAGI3^pPA ^*isoform are shown, with major cis-acting sequences responsible for proper splicing and repression of premature polyadenylation annotated: splice junction location and U1 snRNA binding site. The cryptic PAS, downstream cleavage site and poly(A) tail are also annotated. No mutations were detected in any of these sequences.**DOI:** [http://dx.doi.org/10.7554/eLife.14730.005](10.7554/eLife.14730.005)

Accordingly, we interrogated breast cancer cell lines for evidence of previously unannotated protein products of candidate drivers. Immunoblotting across this cell line panel for one such candidate, MAGI3, revealed a number of extra bands in addition to the two full-length protein isoforms, α and β ([Figure 1B](#fig1){ref-type="fig"}). We found that one of these bands, faintly appearing in most of the cell lines, was non-specific to MAGI3 since it could not be depleted by multiple shRNA targeting *MAGI3* ([Figure 1C](#fig1){ref-type="fig"}). However, in MDA-MB-231 breast cancer cells, a strong band of lower molecular weight was observed and could be specifically depleted by RNAi ([Figure 1B and C](#fig1){ref-type="fig"}). Notably, this truncation was not expressed in the non-transformed MCF10A mammary cell line or *TERT*-immortalized human mammary epithelial cells (HMEC) ([Figure 1B and D](#fig1){ref-type="fig"}).

MAGI3 is a scaffolding protein with 2 WW and 6 PDZ domains, along with a catalytically inactive region of homology to the yeast guanylate kinase ([Figure 1E](#fig1){ref-type="fig"}) ([@bib9]). Mass spectrometry (MS) analysis of the immunoprecipitated truncation mapped many peptides corresponding to the N-terminal half of MAGI3, but detected no peptides from the PDZ domains 3--6 that consist of the C-terminal half of MAGI3 ([Figure 1F](#fig1){ref-type="fig"}). To identify the genetic alteration responsible for this truncation, we sequenced all 22 exons and flanking intron sequences of *MAGI3* but found no mutations. This indicated that the truncation is not generated by DNA mutation of the *MAGI3* coding sequence or splice sites. We subsequently used 3′ rapid amplification of cDNA ends (RACE) to isolate the transcript responsible for the truncated MAGI3 protein. This yielded a truncated *MAGI3* mRNA isoform corresponding to the size and mapped regions of the truncated protein ([Figure 1G](#fig1){ref-type="fig"}). Sequencing the 3′ end of the mRNA revealed a cleavage and polyadenylation event involving a cryptic poly(A) signal (PAS) located in *MAGI3* intron 10 ([Figure 1H](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). Consequently, the normal splicing event from exon 10 to exon 11 of *MAGI3* does not occur in the truncated mRNA (*MAGI3^pPA^*), resulting in a stop codon several nucleotides into intron 10 and premature transcription termination following the cryptic intronic PAS ([Figure 1H](#fig1){ref-type="fig"}).

Local cis-acting DNA mutations in upstream U1 snRNA binding sites or downstream U-rich elements (URE) can affect splicing as well as cleavage and polyadenylation ([@bib18]; [@bib4]; [@bib2]; [@bib29]). Therefore, we sequenced the entire *MAGI3* intron 10 from MDA-MB-231 cells but were unable to find any mutations ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). We also sequenced the entire region of the *MAGI3^pPA ^*3′ RACE product corresponding to intron 10 and the flanking exon 10 sequence, but again uncovered no mutations ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). Notably, the known cis-acting sequences involved in proper splicing and repression of pPA, including the upstream/downstream splice donors, upstream U1 snRNA binding site and downstream URE, were intact in the sequencing analyses ([Figure 1H](#fig1){ref-type="fig"} and [Figure 1---figure supplements 1](#fig1s1){ref-type="fig"} and [2](#fig1s2){ref-type="fig"}). We thus conclude that this pPA event in intron 10 of *MAGI3* arises independently of local genetic mutations. However, we cannot exclude the possibility that a long-range, non-coding mutation in *MAGI3* might play a role in this phenomenon.

Evidence for recurrent generation of *MAGI3^pPA^* in human breast cancer {#s2-2}
------------------------------------------------------------------------

To determine whether the pPA product of *MAGI3* is physiologically relevant in the context of primary human breast tumors, we analyzed whole transcriptome shotgun sequencing (RNA-Seq) data made available by The Cancer Genome Atlas (TCGA) and a previously published RNA-Seq study ([@bib35]). We focused on data collected from primary breast tumors and matched normal tissues in order to establish whether pPA of *MAGI3* is tumor-specific and recurrent. In total, these data included 160 primary breast tumors along with 160 matched, tumor-adjacent normal samples.

Since large differences in *MAGI3* sequencing depth between the two sets of samples might bias detection of pPA events, we first compared sequencing depth of *MAGI3* between tumor and normal RNA-Seq data and found it to be comparable, with only a 1.1-fold median increase in tumor samples. We subsequently used a three-tiered strategy to identify occurrences of *MAGI3^pPA ^*in the data ([Figure 2A](#fig2){ref-type="fig"}). To start, we calculated the genome coverage of total mappable reads for each sample and then asked if intronic reads are present in *MAGI3* intron 10. The vast majority of tumor-adjacent normal samples (157 out of 160) had either no intronic reads or a few, isolated reads; only three samples exhibited long stretches of overlapping intronic reads ([Figure 2A](#fig2){ref-type="fig"}). In comparison, a larger fraction of primary tumors (26 out of 160) were observed with extended stretches of overlapping *MAGI3* intron 10 reads ([Figure 2A](#fig2){ref-type="fig"}).10.7554/eLife.14730.006Figure 2.Premature polyadenylation of *MAGI3* is a recurrent, tumor-specific event in breast cancer.(**A**) Summary of RNA-Seq analysis, statistical tests, and thresholds used to identify primary tumor and matched, tumor-adjacent normal samples expressing *MAGI3^pPA^*. Genome coverage of total mappable reads were quantified for each sample, and read coverage across the tenth intron of *MAGI3* was analyzed. Samples with sustained stretches of overlapping reads were identified and statistically analyzed for read patterns consistent with intron retention using a χ^2^ test. Samples with read patterns in which the intron retention null hypothesis was rejected (p\<0.05) were further analyzed for continuous read coverage across the pPA-specific region. Samples with large gaps (\>75 nt) or multiple gaps (\>4 gaps) failed to pass the threshold set for *MAGI3^pPA^*. (**B**) Total read coverage (blue) of *MAGI3* intron 10 in two primary breast tumors and matched, tumor-adjacent normal samples. The location of the cryptic PAS is indicated by the red arrowhead. (**C**) Table summary of the percentage of primary breast cancers or matched normal tissues in which premature polyadenylation of *MAGI3* occurs. (**D**) Relative expression levels of *MAGI3^pPA ^*versus full-length *MAGI3α* and *MAGI3β* isoforms in primary breast tumor samples.**DOI:** [http://dx.doi.org/10.7554/eLife.14730.006](10.7554/eLife.14730.006)

Premature polyadenylation and intron retention events can both account for intronic reads in RNA-Seq data. Therefore, our next goal was to rule out any samples with intronic read patterns due to intron retention. While reads unique to pPA events are expected to fall within the pPA-specific intronic interval, reads arising from intron retention should exhibit a more uniform distribution throughout the entire intron. Thus, for intron retention, the expected distribution of reads upstream and downstream of the cryptic PAS in *MAGI3* intron 10 can be compared to the empirical read distributions in the 29 samples with tracts of overlapping intronic reads (26 tumor, 3 normal) ([Figure 2A](#fig2){ref-type="fig"}). Interestingly, seventeen of these samples (16 tumor, 1 normal) showed read distributions that were inconsistent with intron retention (p\<0.05, χ^2^ test) ([Figure 2A](#fig2){ref-type="fig"}).

Next, we evaluated the evidence for *MAGI3^pPA ^*expression in these seventeen samples by examining the continuity of read coverage across the pPA-specific region ([Figure 2A](#fig2){ref-type="fig"}). In this analysis, we defined continuity as having overlapping read coverages across the pPA-specific interval with four or fewer small (\<75 nt) gaps. This eliminated five samples (4 tumor, 1 normal) that had either larger gaps or more than four small gaps in coverage ([Figure 2A](#fig2){ref-type="fig"}). We considered the remaining twelve tumor samples, displaying continuous read signals across the pPA region ([Figure 2B](#fig2){ref-type="fig"}), to express the *MAGI3^pPA ^*isoform. The relative expression levels of the truncated isoform was between 2% to 6% of *MAGI3α* expression levels, but was generally higher than or comparable to *MAGI3β* expression levels ([Figure 2D](#fig2){ref-type="fig"}). The occurrence of the *MAGI3* pPA event in 7.5% (12 out of 160) of primary breast tumors and the absence of this event in matched tumor-adjacent normal tissues (0 out of 160) suggest that it is a tumor-specific and recurrent event that may play an important role in breast cancer pathogenesis ([Figure 2C](#fig2){ref-type="fig"}).

MAGI3^pPA^ and other breast cancer-associated *MAGI3* truncations contribute to malignant transformation {#s2-3}
--------------------------------------------------------------------------------------------------------

To determine whether pPA at the *MAGI3* locus in human breast cancers might affect features of malignancy, we evaluated the role of *MAGI3^pPA^* on anchorage-independent growth ([Figure 3A and B](#fig3){ref-type="fig"}). We took advantage different RNAi sequences targeting *MAGI3* that varied in their efficacy in knocking down levels of the full-length protein. Using two independent *MAGI3*-targeting RNAi sequences ([Figure 3C](#fig3){ref-type="fig"}), we were able to largely deplete MAGI3^pPA^ in MDA-MB-231 cells while not significantly altering levels of full-length MAGI3 ([Figure 1C](#fig1){ref-type="fig"}). This caused a greater than four-fold increase in the relative expression levels of full-length MAGI3 versus MAGI3^pPA^ (FL:truncated) ([Figure 1C](#fig1){ref-type="fig"}). Intriguingly, the loss of MAGI3^pPA^ impaired the growth of MDA-MB-231 cells on soft agar compared to non-silencing Scr control, as shown by the reduced size and number of colonies (p=1.1 x 10^--4^ and 3.4 x 10^--5^ for shMAGI3.4 and shMAGI3.5, respectively) ([Figure 3A and B](#fig3){ref-type="fig"}). These data suggest that the *MAGI3* intron 10 pPA event may have been positively selected by MDA-MB-231 cells during the process of malignant transformation, and thus implicate pPA as a mechanism of alteration capable of contributing to breast cancer.10.7554/eLife.14730.007Figure 3.*MAGI3^pPA^* and a pPA-independent, breast cancer-associated *MAGI3* truncation promote anchorage-independent growth.(**A**) Anchorage-independent growth assays for MDA-MB-231 cells expressing Scr control or two independent shMAGI3 (shMAGI3.4 and shMAGI3.5) sequences that preferentially deplete *MAGI3^pPA^*. Images show representative soft agar fields for the indicated cell lines after two weeks. Scale bar represents 100 µm. (**B**) Quantification of soft agar colonies in the indicated cell lines (n = 3 biological replicates per cell line) after two weeks. Data are presented as mean ± SEM. \*\*\*p\<0.001 (two-tailed Student's t-tests). (**C**) Diagrams of full-length MAGI3 and MAGI3^pPA^ showing the regions targeted by shMAGI3.4 and shMAGI3.5. (**D**) Diagrams of the protein domains of a breast cancer-associated MAGI3 truncation, fused to GFP (MAGI3ΔC-GFP), corresponding to the *MAGI3-AKT3* product caused by a chromosome 1 inversion event identified by whole-genome sequencing ([@bib3]). (**E**) Diagrams of the protein domains of the MAGI3^pPA^ and MAGI3ΔC-GFP truncations. (**F**) Anchorage-independent growth assays for MCF10A-SV40 cells expressing MAGI3ΔC-GFP or GFP control. Images show representative soft agar fields and insets show commonly observed colony sizes for the indicated cell lines after three weeks. Scale bar represents 100 µm. (**G**) Quantification of transformed colonies in the indicated cell lines (n = 3 biological replicates per cell line) after three weeks (upper panel). Immunoblots of MAGI3ΔC-GFP, full-length MAGI3 isoforms, and β-actin levels in the cell lines (lower panels). Data are presented as mean ± SEM. \*\*\*p\<0.001 (two-tailed Student's t-test).**DOI:** [http://dx.doi.org/10.7554/eLife.14730.007](10.7554/eLife.14730.007)

To corroborate these findings, we further asked whether other *MAGI3* truncations found in breast cancer -- generated by known alteration mechanisms -- also exhibit oncogenic properties. A *MAGI3-AKT3* fusion gene, caused by a chromosomal rearrangement involving breakpoints at *MAGI3* intron 9 and *AKT3* intron 1, has been previously identified in breast cancer ([@bib3]). To examine the consequences of this *MAGI3* truncation on its own, we created a corresponding *MAGI3* construct truncated at exon 9 and fused it to GFP (MAGI3ΔC-GFP) ([Figure 3D](#fig3){ref-type="fig"}). Compared to MAGI3^pPA^, which partially retains the PDZ3 domain, MAGI3ΔC-GFP lacks all residues corresponding to PDZ2 and PDZ3 ([Figure 3E](#fig3){ref-type="fig"}). When ectopically expressed along with the SV40 early region in MCF10A cells (MCF10A-SV40), MAGI3ΔC-GFP significantly promoted anchorage-independent growth on soft agar compared to the poor growth of control MCF10A-SV40 cells expressing GFP (p=4.8 x 10^--5^) ([Figure 3F and G](#fig3){ref-type="fig"}). Together, these results suggest that truncated *MAGI3* products, whether generated by pPA or other alteration mechanisms, promote mammary cell transformation.

Full-length MAGI3 interacts with the Hippo effector YAP and inhibits YAP-dependent transformation {#s2-4}
-------------------------------------------------------------------------------------------------

To understand how truncated *MAGI3* causes malignant transformation, we first investigated the function of wild-type *MAGI3*. Because the kinase domain of MAGI3 lacks catalytic activity ([@bib9]), we focused on identifying MAGI3 protein interactors by affinity purification of V5-tagged, full-length MAGI3 in MCF10A cells followed by mass spectrometry (AP-MS). The YAP oncoprotein -- a transcription co-activator that functions as a major effector of the Hippo tumor suppressor pathway -- was identified to be top candidate interactor with MAGI3 ([Figure 4A](#fig4){ref-type="fig"}). SERPINB5, also known as the mammary tumor suppressor Maspin, was also identified as a likely MAGI3 interactor ([Figure 4A](#fig4){ref-type="fig"}). In addition, several tight junction and cellular adhesion molecules were identified by this analysis ([Figure 4A](#fig4){ref-type="fig"} and [Supplementary file 1](#SD1-data){ref-type="supplementary-material"}), validating the AP-MS approach since MAGI3 has been observed to localize to cell junctions ([@bib1]; [@bib9]). Indeed, the subcellular localization of MAGI3 in human breast epithelium is consistent with these previous reports, with tight junction localization in luminal cells and cytoplasmic localization in basal/myoepithelial cells ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}).10.7554/eLife.14730.008Figure 4.MAGI3 interacts with the YAP oncoprotein and suppresses YAP-dependent transformation.(**A**) List of the top candidate MAGI3-interacting proteins in MCF10A cells as identified by AP-MS. (**B**) Endogenous MAGI3/YAP interaction in MCF10A cells by co-IP. Immunoblots of MAGI3 and YAP from input and indicated IP lysates are shown. (**C**) Immunoblots of full-length MAGI3-V5 and either full-length Flag-YAP (left) or mutant Flag-YAPΔC (right), in which the C-terminal YAP PDZ-binding motif (FLTWL) is deleted, from the indicated input and IP lysates (HEK293T cells). (**D**) Immunoblots of full-length YAP and either full-length MAGI3-V5 or PDZ6-deleted MAGI3-V5 from the indicated input and IP lysates (HEK293T cells). (**E**) The relative expression of YAP target genes *ANKRD1* and *CYR61* in MCF10A cells, as determined by qPCR, in cells expressing shMAGI3 or non-silencing Scr control, with or without *MAGI3* cDNA or non-rescuing GFP control (n = 3 technical replicates per cell line). Data are presented as mean ± SEM. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001 (two-tailed Student's t-tests). (**F**) Anchorage-independent growth assays for MCF10A-SV40 cells expressing the indicated shRNA and/or cDNA constructs. Images show representative soft agar fields and insets show commonly observed colony sizes for the indicated cell lines after three weeks. Scale bar represents 100 µm. (**G**) Quantification of transformed colonies in the indicated cell lines (n = 3 biological replicates per cell line) after three weeks (upper panel). Immunoblots of full-length MAGI3 isoforms, YAP and β-actin levels in the cell lines (lower panels). Data are presented as mean ± SEM. \*\*p\<0.01, \*\*\*p\<0.001 (two-tailed Student's t-tests).**DOI:** [http://dx.doi.org/10.7554/eLife.14730.008](10.7554/eLife.14730.008)10.7554/eLife.14730.009Figure 4---figure supplement 1.MAGI3 expression and localization in normal human mammary epithelial cells.(**A**) Immunofluorescence of reduction mammoplasty tissue showing MAGI3 (red) expression and colocalization with the basal epithelial cell marker, KRT14 (green). Scale bar represents 50 µm. (**B**) Immunofluorescence of reduction mammoplasty tissue showing MAGI3 (red) colocalization with the tight junction protein ZO-1 (green) in human mammary luminal cells. Scale bar represents 50 µm. (**C**) Immunofluorescence of reduction mammoplasty and high magnification of MAGI3 (red) localization in the cytoplasm of basal/myoepithelial cells. DAPI (blue) was used to visualize nuclei. Scale bar represents 10 µm.**DOI:** [http://dx.doi.org/10.7554/eLife.14730.009](10.7554/eLife.14730.009)

Since the YAP oncoprotein was by far the top interacting protein with MAGI3 ([Supplementary file 1](#SD1-data){ref-type="supplementary-material"}), we performed reciprocal co-immunoprecipitation (co-IP) experiments for endogenous MAGI3 and endogenous YAP to validate their interaction. Indeed, we found that YAP co-immunoprecipitated with MAGI3 and likewise, MAGI3 co-immunoprecipitated with YAP from MCF10A cell lysates ([Figure 4B](#fig4){ref-type="fig"}). We next determined the critical domains necessary for interaction between MAGI3 and YAP by ectopically expressing various epitope-tagged full-length and deletion mutants of MAGI3 and YAP in HEK293T cells. To determine whether this interaction required PDZ domain-binding, we performed co-IP experiments with V5-tagged MAGI3 and either Flag-tagged full-length YAP or a YAP mutant lacking the PDZ-binding motif (YAPΔC) ([@bib26]). Consistent with the endogenous co-IP results, Flag-tagged full-length YAP co-immunoprecipitated with V5-tagged MAGI3 in HEK293T cells ([Figure 4C](#fig4){ref-type="fig"}). However, Flag-YAPΔC and MAGI3-V5 could not be co-immunoprecipitated by either anti-Flag or anti-V5 IP ([Figure 4C](#fig4){ref-type="fig"}), indicating that the PDZ-binding motif of YAP is necessary for the physical interaction between the two proteins. To further confirm that the interaction between YAP and MAGI3 requires PDZ domain-binding, we first utilized a computational predictor to map the PDZ-binding peptide of YAP against all human PDZ domains ([@bib15]) and found that the sixth PDZ domain (PDZ6) of MAGI3 was the highest-scoring interactor on the list ([Supplementary file 2](#SD2-data){ref-type="supplementary-material"}). We thus expressed a Flag-tagged *MAGI3* construct lacking PDZ6 (MAGI3ΔPDZ6) in HEK293T cells and performed co-IP experiments for YAP to determine the necessity of PDZ6 for MAGI3 and YAP interaction. Deletion of PDZ6 curtailed MAGI3 interaction with YAP ([Figure 4D](#fig4){ref-type="fig"}). Taken together, these data demonstrate that the PDZ-binding motif of YAP and the PDZ6 domain of MAGI3 are necessary for protein-protein interaction.

Having shown that full-length MAGI3 and YAP interact endogenously, we next investigated whether manipulating MAGI3 levels affects the ability of YAP to act as a transcription co-activator. When MCF10A cells were depleted of *MAGI3* by RNAi, the expression of YAP target genes *ANKRD1* and *CYR61* were induced (p=9.9 x 10 ^--3^ and 2.5 x 10^--4^, respectively), as determined by quantitative real-time PCR (qPCR) ([Figure 4E](#fig4){ref-type="fig"}). The rescue of *MAGI3* levels restored the expression of *ANKRD1* and *CYR61* to baseline levels (p=0.012 and 3.5 x 10^--4^, respectively) ([Figure 4E](#fig4){ref-type="fig"}), thus demonstrating the specificity of YAP regulation by *MAGI3*. We next developed a phenotypic assay to determine whether the molecular interactions between MAGI3 and YAP are physiologically relevant. Because RNAi-mediated knockdown of *MAGI3* in MCF10A-SV40 cells causes anchorage-independent growth (p=1.4 x 10^--3^) ([Figure 4F and G](#fig4){ref-type="fig"}), and overexpression of YAP in MCF10A cells also causes transformation ([@bib27]), we used the transformed phenotype to conduct epistasis analysis between *MAGI3* and *YAP1*. Knockdown of *YAP1* in *MAGI3*-depleted cells restored the normal phenotype (p=4.9 x 10^--5^ and 8.9 x 10^--4^ for shYAP1 \#1 and \#2, respectively), as did restoring *MAGI3* expression in *MAGI3*-depleted cells (p=6.5 x 10^--7^ and 2.0 x 10^--5^ for MAGI3α and MAGI3β, respectively) ([Figure 4F and G](#fig4){ref-type="fig"}). Collectively, these data suggest that the protein-protein interaction between MAGI3 and YAP is physiologically relevant for the negative regulation of YAP by full-length MAGI3.

Oncogenic MAGI3 truncations activate YAP by dominantly suppressing full-length MAGI3/YAP interactions {#s2-5}
-----------------------------------------------------------------------------------------------------

Having obtained an understanding of the relationships between full-length MAGI3, YAP and malignant transformation, we proceeded to investigate the functional differences between truncated and full-length MAGI3. YAP functions as a transcriptional coactivator, and the regulation of its subcellular localization is a major determinant of protein activity ([@bib42]). In HEK293T cells, YAP activity exhibits highly robust responses to serum deprivation, which promotes cytoplasmic accumulation of YAP, and subsequent serum stimulation, which rapidly induces YAP nuclear translocation ([@bib41]). Thus, we examined the subcellular localization of YAP in cells transfected with either truncated or full-length MAGI3. Consistent with the *MAGI3* loss-of-function data, overexpression of full-length MAGI3 led to YAP cytoplasmic accumulation despite serum stimulated cell culture, whereas nuclear translocation of YAP was induced in untransfected control cells ([Figure 5A and B](#fig5){ref-type="fig"}). By contrast, the expression of truncated MAGI3 caused the opposite effect by increasing nuclear YAP localization in cells even under the serum deprived conditions that normally preclude YAP from the nucleus ([Figure 5C and D](#fig5){ref-type="fig"}). The increased nuclear YAP localization was indicative of heightened YAP activation, since the amount of phosphorylated/inactive YAP was reduced in lysates from cells expressing MAGI3^pPA^ and MAGI3ΔC-GFP compared to GFP control ([Figure 5E](#fig5){ref-type="fig"}). Thus, in contrast to the inhibitory effect of full-length MAGI3 on YAP, these data demonstrate that truncated MAGI3 is positively associated with YAP activation. We further asked whether the transformed phenotype caused by expression of truncated MAGI3 is YAP-dependent. Indeed, knockdown of YAP in MCF10A-SV40 cells expressing MAGI3ΔC-GFP resulted in a significant reduction of colony formation on soft agar (p=7.4 x 10^--5^) ([Figure 5F and G](#fig5){ref-type="fig"}), suggesting that the increase in YAP activity caused by truncated MAGI3 is functionally important for transformation.10.7554/eLife.14730.010Figure 5.Expression of truncated MAGI3 leads to increased YAP activation and YAP-dependent transformation.(**A-B**) Immunofluorescence of serum-stimulated HEK293T cells showing YAP (red) localization. GFP positivity indicates full-length MAGI3-transfected cells. DAPI (blue) was used to visualize nuclei. (**A**) Field containing predominantly untransfected cells is shown. (**B**) Field containing MAGI3-transfected cells is shown. (**C-D**) Immunofluorescence of serum-deprived HEK293T cells showing YAP (red) localization. GFP indicates expression and localization of MAGI3ΔC-GFP. DAPI (blue) was used to visualize nuclei. (**C**) Field containing predominantly untransfected cells is shown. (**D**) Field containing MAGI3ΔC-GFP-transfected cells is shown. (**E**) Immunoblots of V5-tagged MAGI3^pPA^, MAGI3ΔC-GFP, Ser127-phosphorylated YAP, total YAP and β-actin levels in HEK293T cells transfected as indicated. The relative levels of Ser127-phosphorylated YAP in the indicated lysates are normalized to total YAP levels. (**F**) Anchorage-independent growth assays for MCF10A-SV40 cells expressing MAGI3ΔC-GFP with or without shYAP1. Images show representative soft agar fields for the indicated cell lines after three weeks. Scale bar represents 100 µm. (**G**) Quantification of transformed colonies in the indicated cell lines (n = 3 biological replicates per cell line) after three weeks (upper panel). Immunoblots of YAP and β-actin levels in the cell lines (lower panels). Data are presented as mean ± SEM. \*\*\*p\<0.001 (two-tailed Student's t-tests).**DOI:** [http://dx.doi.org/10.7554/eLife.14730.010](10.7554/eLife.14730.010)

Since truncated MAGI3 induces YAP activation and anchorage-independent growth, whereas full-length MAGI3 suppresses YAP activity and the transformed phenotype, we hypothesized that the MAGI3 truncation products found in breast cancer possess dominant-negative activity. Indeed, the presence of truncated MAGI3 was sufficient to prevent endogenous, full-length MAGI3 from interacting with YAP ([Figure 6A](#fig6){ref-type="fig"}). However, because both MAGI3^pPA^ and MAGI3ΔC-GFP lack the PDZ6 domain required for interaction with YAP ([Figure 4D](#fig4){ref-type="fig"}), neither truncation was able to physically associate with YAP ([Figure 6B and C](#fig6){ref-type="fig"}). The absence of physical interaction between truncated MAGI3 and YAP demonstrates that truncated MAGI3 proteins do not directly compete with full-length MAGI3 for YAP binding.10.7554/eLife.14730.011Figure 6.Dominant-negative MAGI3 truncations interact with full-length MAGI3 proteins to interfere with MAGI3/YAP interaction.(**A**) Immunoblots of full-length endogenous MAGI3, endogenous YAP, V5-tagged MAGI3^pPA^ and MAGI3ΔC-GFP from the indicated input and IP lysates (HEK293T cells). (**B**) Immunoblots of V5-tagged MAGI3^pPA^, full-length MAGI3-V5 and endogenous YAP from the indicated input and IP lysates (HEK293T cells). (**C**) Immunoblots of MAGI3ΔC-GFP, full-length MAGI3-GFP and endogenous YAP from the indicated input and IP lysates (HEK293T cells). ([**D**]{.smallcaps}) Immunoblots of full-length MAGI3-GFP and V5-tagged MAGI3^pPA^ from the indicated input and IP lysates (HEK293T cells). (**E**) Immunoblots of MAGI3ΔC-GFP and endogenous full-length MAGI3 from the indicated input and IP lysates (HEK293T cells). (**F**) Quantification of tumor mass (left panel) and photograph (right panel) of MDA-MB-231 cells grown as orthotopic xenografts in NOD/SCID mice. Tumors with high ratios of FL:pPA MAGI3 (n = 5 mice) or unmodified control ratios (n = 4 mice) are indicated. Data are plotted as individual data points along with mean ± SD. \*\*\* p\<0.001 (two-tailed Student's t-tests). (**G**) The relative expression ratios of FL:pPA mRNA in control- (n = 4) or high-ratio (n = 5) MDA-MB-231 tumor xenografts, as determined by qPCR. Data are presented as mean ± SEM. \*\* p\<0.01 (two-tailed Student's t-test).**DOI:** [http://dx.doi.org/10.7554/eLife.14730.011](10.7554/eLife.14730.011)

We next asked whether truncated MAGI3 proteins might physically associate with full-length MAGI3. By co-immunoprecipitation, we found that truncated and full-length MAGI3 proteins do indeed physically interact ([Figure 6D and E](#fig6){ref-type="fig"}). These results suggest that the ability of truncated MAGI3 proteins to form complexes with full-length MAGI3 interferes with physiological MAGI3/YAP interactions. To further confirm that truncated MAGI3 behaves in this dominant-negative manner, we expressed full-length *MAGI3* in MDA-MB-231 cells to induce stoichiometric gains of full-length MAGI3 versus MAGI3^pPA^ (FL:pPA). Alongside these cells, we generated FL:pPA ratio-unmodified controls by stably transducing MDA-MB-231 cells with empty vector GFP. Both pools of cells were orthotopically implanted into female NOD/SCID mice, and tumor growth was monitored over a seven-week timespan. Consistent with the mechanism, the growth of tumors expressing high ratios of FL:pPA was significantly impaired compared to FL:pPA ratio-unmodified control tumors (p=5.8 x 10^--5^) ([Figure 6F and G](#fig6){ref-type="fig"}). Collectively, these data demonstrate that the recurrent *MAGI3^pPA^* product and other breast cancer-associated MAGI3 truncations suppress the inhibitory interaction between full-length MAGI3 and YAP, thus providing a molecular link between their dominant-negative activity and their oncogenic nature.

Discussion {#s3}
==========

In this study, we have identified a breast cancer-associated pPA event at a cryptic intronic PAS in *MAGI3*, resulting in the production of a truncated, oncogenic gene product. We have shown that truncations of MAGI3 generated by pPA as well as other mechanisms of alteration promote increased activation of the Hippo effector YAP and induce YAP-dependent malignant transformation. These effects are mediated by the dominant-negative activity of MAGI3 truncations, which physically associate with full-length MAGI3 and antagonize the inhibitory protein-protein interaction between full-length MAGI3 and YAP. Thus, the interaction between full-length MAGI3 and YAP plays a central role in suppressing malignant transformation ([Figure 7](#fig7){ref-type="fig"}). Furthermore, our identification and functional characterization of *MAGI3^pPA ^*establishes that pPA can contribute to cancer by utilizing cryptic intronic PAS to generate truncated mRNA isoforms encoding oncoproteins.10.7554/eLife.14730.012Figure 7.Model for the mechanism by which premature polyadenylation of *MAGI3* contributes to malignant transformation.In normal cells, the proper post-transcriptional processing of transcripts produced by the *MAGI3* gene locus gives rise to full-length MAGI3 proteins that negatively regulate the YAP oncoprotein by forming an inhibitory complex. In cancer cells, premature polyadenylation of *MAGI3* results in the production of truncated MAGI3 proteins in addition to full-length MAGI3. Truncated MAGI3 is unable to bind YAP but can interact with full-length MAGI3. This dominant-negative interaction may prevent full-length MAGI3 from forming an inhibitory complex with YAP, thus resulting in YAP-mediated malignant transformation.**DOI:** [http://dx.doi.org/10.7554/eLife.14730.012](10.7554/eLife.14730.012)

The tumor suppressive role of MAGI3/YAP interactions {#s3-1}
----------------------------------------------------

In the past, a number of observations have supported the possibility that *MAGI3* may be involved in cancer. For example, oncogenic human papillomaviruses, which have evolved to target critical tumor suppressors necessary for transformation such as p53, also target MAGI3 for degradation ([@bib34]). In addition, *MAGI3* was found to be part of a downregulated gene signature associated with breast tumor-initiating cells ([@bib6]). However, a specific role for *MAGI3* as a tumor suppressor in human cancer has remained elusive, due to the apparent infrequent alteration of the gene in cancer and the lack of cancer-relevant mechanistic evidence.

In human cancer, *MAGI3* is not frequently altered by nonsynonymous mutations or copy number losses ([@bib5]; [@bib10]), and has not been previously nominated as a driver. Here, we have found evidence that a single alteration event in *MAGI3*, caused by the utilization of a cryptic intron 10 PAS by premature cleavage and polyadenylation, occurs in approximately 7.5% of 160 breast cancers analyzed, and the resulting truncated *MAGI3* product contributes to the malignant transformation of human mammary epithelial cells. Transformation caused by an independent MAGI3 truncation, also found in breast cancer, provides additional functional evidence for the cancer relevance of MAGI3 truncations. Moreover, the ability of these truncations to function as dominant-negative proteins and prevent the inhibition of YAP by full-length MAGI3 suggests that the generation of truncated *MAGI3* products by pPA or chromosomal rearrangement may more potently deregulate YAP activity and drive transformation compared to the mutation or loss of a single *MAGI3* allele. Collectively, these data indicate that *MAGI3* alterations in cancer may occur much more frequently than previously appreciated and support the clinical relevance of MAGI3 truncations as driver alterations.

By defining the protein-protein interaction network of MAGI3, we have uncovered the previously unknown interaction between MAGI3 and YAP, an oncoprotein that represents the major downstream effector of the Hippo tumor suppressor pathway ([@bib28]; [@bib17]). We have demonstrated that these YAP-inhibitory interactions play an important role in suppressing malignant transformation, since reduction of these functional complexes by depleting full-length MAGI3 leads to increased YAP-dependent transcriptional activation and transformation. Importantly, we found that the C-terminal PDZ6 domain of MAGI3 is essential for MAGI3/YAP interaction, whereas the two independent breast cancer-associated MAGI3 truncations studied here -- MAGI3^pPA^ and MAGI3ΔC -- lack this domain and fail to interact with YAP. Nevertheless, the truncations dominantly suppressed interactions between full-length MAGI3 and YAP, resulting in YAP activation and malignant transformation. We further determined that MAGI3 truncations can physically associate with full-length MAGI3 proteins, and thus posit that this aberrant complex interferes with the interaction between full-length MAGI3 and YAP. Our results underscore the importance of the MAGI3/YAP interaction in suppressing malignant transformation and implicate MAGI3 as a new potential component involved in the regulation of the Hippo tumor suppressor pathway. In addition, our identification of other candidate protein-protein interactors of MAGI3 establishes a resource for future investigation into other biological processes regulated by full-length MAGI3 protein.

Premature cleavage and polyadenylation as a cancer-relevant alteration mechanism {#s3-2}
--------------------------------------------------------------------------------

An emerging phenomenon in cancer is the generation of gene expression alterations by localized mutational or transcriptome-wide events affecting cleavage and polyadenylation. In mantle cell lymphoma, for example, mutations that generate novel, gene-proximal PAS in the *CCND1* 3′ UTR have been discovered. In these tumors, the production of shorter, prematurely polyadenylated cyclin D1 mRNA isoforms, which exhibit dramatically extended half-lives, drive the overexpression of cyclin D1 oncoproteins ([@bib37]). In addition, a number of studies on genes with tandem PAS arrangements in the 3′ UTR have shown that shorter 3′ UTRs utilizing the gene-proximal PAS are favored by cancer cells ([@bib31]; [@bib32]; [@bib21]; [@bib39]). This increased tendency in cancer cells to utilize gene-proximal PAS for cleavage and polyadenylation corresponds to increased mRNA half-life as well as protein expression ([@bib32]; [@bib21]), suggesting that 3′ UTR shortening may be a general mechanism of evading regulation by tumor suppressive microRNAs.

Our study extends these previous findings by showing that, in cancer, premature cleavage and polyadenylation can occur in the intron of a gene despite the absence of mutations in the immediate exon/intron sequences flanking the cryptic PAS. While alternative 3′ UTR PAS selection does not alter the mRNA coding potential, pPA can cause gene-truncating alterations that produce pre-mRNAs with potential to encode constitutively active or dominant-negative proteins. Such pre-mRNAs are naturally able to evade post-transcriptional quality-control surveillance mechanisms such as nonsense-mediated mRNA decay. By producing constitutively active or dominant-negative proteins, pPA transcripts may cause significant functional and phenotypic consequences even if expressed at lower levels than wild-type mRNA isoforms. Determining whether pPA events in cancer occur in other genes beside *MAGI3,* and whether pPA is triggered widely throughout the transcriptome or focally restricted to susceptible intronic PAS, are important future directions but beyond the scope of the current study. However, pPA truncation of other cancer-relevant genes is a strong possibility considering the previous studies that have identified dominant-negative proteins arising from pPA events. Prominent examples of these pPA-generated dominant-negative proteins include an EPRS isoform in peripheral blood monocytes that blocks translational repression by full-length EPRS following γ-interferon activation ([@bib40]), and a VEGFR2 truncation that inhibits HUVEC tube formation in vitro ([@bib36]). Given these precedents, it will be important to conduct transcriptome-scale studies to identify other genes affected by premature polyadenylation in cancer. Such studies, however, must await the development of custom pPA-finding computational methods.

The results of our study also pose several intriguing mechanistic questions. For example, how do pPA events arise independently of local, cis-acting genetic mutations? Previous work has shown that, under certain conditions, pPA events can be induced in cells. For example, U1 snRNP function is essential for protecting pre-mRNAs from pPA at cryptic intronic PAS ([@bib18]; [@bib2]), and experimental depletion of U1 snRNP levels can lead to the production of novel, pPA-truncated isoforms that encode dominant-negative proteins ([@bib36]). Overexpression of polyadenylation factors has also been shown to mediate alternative intronic PAS usage ([@bib33]). These findings raise the possibility that alteration of a *trans*-acting factor in cancer cells could result in either focal or transcriptome-wide pPA. Moreover, because the relative abundance of U1 snRNP to nuclear pre-mRNAs is a critical factor for determining whether global pPA events occur ([@bib4]), alterations that drive global transcriptional amplification, a phenomenon frequently observed in cancer cells ([@bib24]; [@bib20]; [@bib30]; [@bib7]), might also induce pPA. In addition, whether broad pPA induction enables cancer cells to sample and select specific pPA events that confer functional growth advantages -- such as *MAGI3^pPA^* -- and how pPA events at the functionally relevant loci are passed from mother cell to daughter cells, are outstanding questions that will require further investigation into the phenomenon of pPA in cancer.

Materials and methods {#s4}
=====================

Cloning and plasmid construction {#s4-1}
--------------------------------

Full-length *MAGI3* isoforms concordant with NCBI RefSeq transcripts were amplified from MCF10A cDNA and subcloned into pLenti7.3-V5-DEST (Thermo Fisher Scientific, Waltham, MA) or CS-CG ([@bib22]) for MAGI3-V5 and MAGI3-GFP, respectively. Truncated *MAGI3* isoforms were amplified from using internal, sequence-specific primers. MAGI3ΔPDZ6 was subcloned into pcDNA3.0-Flag-HA (Addgene, Cambridge, MA). MAGI3ΔC was subcloned into CS-CG to generate MAGI3ΔC-GFP. MAGI3^pPA^ was subcloned into pLenti7.3-V5-DEST. shMAGI3 (TRCN0000037865), shMAGI3.4 (TRCN0000037867) and shMAGI3.5 (TRCN0000037868) were subcloned into pLKO.1-puro. *YAP1* shRNAs (TRCN0000107265 and TRCN0000107267) were subcloned into pLKO.1-hygro. Expression vectors for SV40 early region, Scr shRNA, Flag-YAP, and Flag-YAPΔC have been described previously ([@bib25]; [@bib26]; [@bib38]; [@bib23]).

Cell lines and tissue culture {#s4-2}
-----------------------------

Cell lines used in this study (MDA-MB-231, MCF10A, BT-20, HCC 70, HCC 1806, HCC 1937 and HEK293T) were purchased from ATCC (Manassas, VA), which have been authenticated by short tandem repeat DNA profiling and are free of mycoplasma contamination. Other cell lines were obtained from Dr. Stephen Ethier (SUM lines) or established in our laboratory (HMEC). Cells were grown at 37°C with 5% CO~2~ and cultured in DMEM supplemented with 10% fetal bovine serum unless otherwise noted. MCF10A cells were cultured in complete MEGM (Lonza, Switzerland) plus 100 ng/ml cholera toxin. HMECs were cultured in complete MEGM (Lonza). SUM lines were cultured in Ham's F12 supplemented with 5% fetal bovine serum, 5 µg/ml insulin and 0.5 µg/ml hydrocortisone. For serum starvation, cells were incubated for 24 hr in media without supplements. Subsequent serum stimulation was performed by adding FBS to a final concentration of 10% and incubation for 30 m. Transfections were performed using FuGENE HD (Promega, Madison, WI). For lentivirus production, HEK293T cells were co-transfected with pCMV-VSV-G, pCMV-ΔR8.2-Δvpr, and lentiviral expression vectors. For the generation of cell lines, MCF10A and MDA-MB-231 cells were incubated overnight in viral supernatants supplemented with 5 µg/ml protamine sulfate and subsequently selected by antibiotics or FACS. Cell lines harboring multiple genetic manipulations were created by serial transductions.

RNA isolation and downstream applications {#s4-3}
-----------------------------------------

Total RNA was isolated using the RNeasy Mini Kit (Qiagen, Germany) and treated with DNase I (Roche, Switzerland) to remove any contaminating DNA. For 3′ RACE, cDNA was synthesized by reverse transcription using Superscript II RTase and an oligo(dT)-containing adapter primer to poly(A) mRNA (Thermo Fisher Scientific). Subsequently, a nested PCR method was used to amplify *MAGI3* transcripts. The primary reaction utilized a *MAGI3*-specific forward primer (M3Q2-F) and a unique amplification primer (UAP-R) to the oligo(dT)-containing adapter primer, and the secondary reaction utilized *MAGI3*-specific forward primers downstream of M3Q2-F (M3-F12 and M3-F13). The 3′ ends of resulting products were sequenced by Sanger sequencing. Primer sequences used for 3′ RACE are listed in [Table 1](#tbl1){ref-type="table"}.10.7554/eLife.14730.013Table 1.Primer sequences used for 3′ RACE.**DOI:** [http://dx.doi.org/10.7554/eLife.14730.013](10.7554/eLife.14730.013)NamePrimer Sequence (5′ to 3′)M3Q2-FCTGTGTCCTCGGTCACACTCM3-F12TATCCATGGCATCGTCAGGCM3-F13GTTGCTGCTACCCCTGTCATUAP-RGGCCACGCGTCGACTAGTAC

For real-time PCR (qPCR), cDNA was first synthesized from total RNA by reverse transcription using the iScript cDNA synthesis kit (Biorad, Hercules, CA). Samples were diluted for reactions with gene-specific primers and SYBR green (Bioline, Taunton, MA) using the CFX96 Real-Time System (Biorad). qPCR was performed in triplicate for each sample-target combination, and mRNA abundance was normalized to *GAPDH*. Primer sequences are listed in [Table 2](#tbl2){ref-type="table"}.10.7554/eLife.14730.014Table 2.Primer sequences used for qPCR.**DOI:** [http://dx.doi.org/10.7554/eLife.14730.014](10.7554/eLife.14730.014)GeneForward Primer (5′ to 3′)Reverse Primer (5′ to 3′)ANKRD1AGTAGAGGAACTGGTCACTGGTGGGCTAGAAGTGTCTTCAGATCYR61GGTCAAAGTTACCGGGCAGTGGAGGCATCGAATCCCAGCGAPDHCCATGGGGAAGGTGAAGGTCTAAAAGCAGCCCTGGTGACCMAGI3 (FL)AGCAGTTTCCAGTAGGTGCTTGTCGTCCTCGGGTTGTTTTMAGI3 (pPA)AGCAGTTTCCAGTAGGTGCTGAGGTCCAGATGACACACCA

Protein isolation and downstream applications {#s4-4}
---------------------------------------------

For immunoprecipitation experiments, cells were suspended in Tris-HCl buffer (20 mM Tris-HCl, pH 7.5) supplemented with protease/phosphatase inhibitors, lysed by dounce homogenizer, pre-cleared by incubating with Protein A Dynabeads (Thermo Fisher Scientific) for 1 hr, then incubated with antibodies overnight. Complexes were then bound to Protein A Dynabeads for 1 hr, washed three times with Tris-HCl buffer and eluted by boiling in SDS loading buffer. To isolate protein from whole-cell lysates for immunoblotting, cells were lysed in RIPA buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.5% sodium deoxycholate, 0.1% SDS, 1% NP-40) supplemented with protease inhibitors (Roche) phosphatase inhibitors (Sigma-Aldrich, St. Louis, MO). Protein samples were separated by SDS-PAGE according to standard procedures, transferred onto nitrocellulose membranes and blocked with 5% milk. Immunoblotting was performed according to standard procedures and protein detection was visualized using enhanced chemiluminescence (Thermo Fisher Scientific). For protein mass spectrometry, MAGI3 IP lysates were separated by SDS-PAGE, fixed in the gel, stained with a 0.3% Coomassie Blue R250 solution, then destained overnight. The gel slice containing the truncated MAGI3 protein from MDA-MB-231 cells was excised, digested and analyzed by liquid chromatography-tandem mass spectrometry (Taplin Mass Spectrometry Facility, Harvard Medical School). For identification of MAGI3-interacting proteins from MCF10A cells, the gel was partitioned into six sections for digestion and downstream analysis. The accepted list of interacting proteins was obtained by subtracting common contaminants (CRAPome). Antibodies used in the above applications are listed in [Table 3](#tbl3){ref-type="table"}.10.7554/eLife.14730.015Table 3.Antibodies used in this study.**DOI:** [http://dx.doi.org/10.7554/eLife.14730.015](10.7554/eLife.14730.015)AntibodyHostVendor/catalog numberIBIPIFβ-actinMouseAbcam (Cambridge, MA) ab6276Flag (HRP-)RabbitCell Signaling Technology (Danvers, MA) 2044XFlagMouseSigma-Aldrich F3165XGFPRabbitAbcam ab290XXKRT14MouseVector Laboratories (Burlingame, CA) VP-C410XMAGI3MouseAbcam ab11509XMAGI3RabbitNovus Biologicals (Littleton, CO) NBP2-17210XXXmouse (Alexa488-)GoatThermo Fisher Scientific A11001Xmouse (HRP-)GoatCell Signaling Technology 7076Xnormal IgGMouseSanta Cruz Biotechnology (Dallas, TX) sc-2025Xnormal IgGRabbitSanta Cruz Biotechnology sc-2027Xrabbit (Alexa546-)GoatThermo Fisher Scientific A11010Xrabbit (HRP-)GoatCell Signaling Technology 7074XV5 (HRP-)RabbitAbcam ab1325XV5MouseThermo Fisher Scientific R960XXYAPMouseSanta Cruz Biotechnology sc-101199XXXYAPRabbitSanta Cruz Biotechnology sc-15047XXp-YAP Ser 127RabbitCell Signaling Technology 4911XZO-1MouseT 339100X

Immunofluorescence {#s4-5}
------------------

Disease-free human breast tissue was obtained in compliance with the laws and institutional guidelines as approved by the Tufts Medical Center Institutional Review Board Committee. The approval number for human subject research is 00004517. The tissue was obtained from patients undergoing elective reduction mammoplasty. De-identified breast tissue was utilized for this study, and for this reason informed consent was not required. For paraffin-embedded human mammary tissues, sections were deparaffinized and rehydrated prior to heat-induced antigen retrieval in Tris-EDTA (10 mM Tris, pH 9.0, 1 mM EDTA, 0.05% Tween 20). Cultured cells seeded on coverslips were fixed in 4% paraformaldehyde and permeabilized in 0.1% Triton-X 100 in PBS. Samples were blocked in 3% normal goat serum for 1 hr at room temperature prior to incubation with primary antibodies overnight. Alexa488- and Alexa546-conjugated secondary antibodies were used to detect proteins and 1 µg/ml DAPI was used to visualize nuclei. Samples were mounted on glass slides with the SlowFade Antifade Kit (Thermo Fisher Scientific). Antibodies used for immunofluorescence are listed in [Table 3](#tbl3){ref-type="table"}.

Transformation and orthotopic tumor xenograft assays {#s4-6}
----------------------------------------------------

For soft agar transformation assays, 10^4^ cells were suspended in a 0.4% Seaplaque agarose:culture media mixture and layered onto 0.8% agarose in DMEM. Fresh growth medium was provided weekly. Colonies were imaged, stained with 0.005% crystal violet and quantified (colonies ≥ 100 µm diameter) after 14 days (MDA-MB-231) or 21 days (MCF10A). For orthotopic tumor xenograft assays, all procedures were performed in accordance with the animal protocol approved by the Tufts University Institutional Animal Care and Use Committee. The approval number for animal research is A-3775-01. Prior to surgery, 10-week old, female NOD/SCID mice (The Jackson Laboratory, Bar Harbor, ME) were anesthetized by isoflurane vapor. An incision was made along the right flank to expose the inguinal mammary gland, and 1 x 10^6^ cells in a total volume of 25 µl 1:1 Matrigel:phosphate-buffered saline were injected into the gland. Post-operative analgesic and monitoring were provided. Animals were sacrificed after 7 weeks, and tumors were dissected and weighed.

Bioinformatic analysis of RNA-seq data {#s4-7}
--------------------------------------

Sequence alignment data and normalized gene expression data for primary breast tumors and matched, tumor-adjacent normal tissues were downloaded from the Cancer Genomics Hub, TCGA data portal, the NCBI Sequence Read Archive (SRA) and the Gene Expression Omnibus (GEO). The identifiers for the SRA and GEO datasets are SRP042620 and GSE58135 ([@bib35]). To evaluate sequencing depth for *MAGI3* in primary tumor and tumor-adjacent normal tissues of the two datasets, we compared upper quartile-normalized TPM (transcripts per million) or FPKM (fragments per kilobase of transcript per million mapped reads) values for *MAGI3.* To identify putative pPA events, we calculated the genome coverage of total mappable reads for each sample by using the BEDtools *genomecov* script and converted the output to BEDGRAPH files for subsequent analyses using the UCSC genome browser. Next, we inspected each sample for evidence of read coverage across *MAGI3* intron 10, allowing us to group samples into two categories: (1) samples with no intronic reads or only a few, isolated intronic reads; (2) samples with sustained stretches of overlapping intronic reads. The intronic read distributions of samples in Group 2 were further analyzed by a χ^2^ goodness-of-fit test to evaluate the null hypothesis---namely, that the observed distribution of sequencing reads occurs due to intron retention. This was performed by splitting *MAGI3* intron 10 into two regions: (A) the pPA-specific region from the start of the intron to the cryptic PAS; (B) the intronic region downstream of the cryptic PAS. A p\<0.05 was considered a significant deviation from the expected read distribution and therefore a rejection of the null hypothesis. Samples with p\<0.05 were further analyzed for continuity of read coverage throughout Region A. To account for non-uniformity biases inherent in RNA-Seq read distributions, we set a threshold for continuity defined by overlapping read coverage with fewer than 5 small (\<75 nt) gaps. Samples passing all the above criteria were considered to express the pPA-truncated *MAGI3* isoform, and relative expression levels of *MAGI3^pPA ^*versus either of the full-length isoforms (*MAGI3α* and *MAGI3β*) were measured by counting the number of reads mapping uniquely to each isoform and dividing the length-corrected reads mapping to the pPA isoform by those mapping to each full-length isoform.

Statistical analysis {#s4-8}
--------------------

A power analysis program for comparing two means (two-sample, two-sided equality) was used to determine the sample size needed for experiments, with significance criteria being α = 0.05 and power = 0.8. For these calculations, we assumed a difference between means of 30 and 50 along with standard deviations of 10 and 20 for transformation assays and tumor xenograft experiments, respectively. Data were analyzed and compared between groups using two-tailed Student's t-tests. A p\<0.05 was considered statistically significant.
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Thank you for submitting your article \"Premature Polyadenylation and Truncation of *MAGI3* Contribute to Transformation and Breast Cancer\" for consideration by *eLife*. Your article has been favorably evaluated by Sean Morrison (Senior Editor) and three reviewers, one of whom is a member of our Board of Reviewing Editors.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision. *eLife* is open to reviewing a revised version of the paper, though substantial new data will be required to address the reviewer comments.

Summary:

The authors have identified a C-terminal truncated form of MAGI3 protein as a cancer-promoting variant. Interestingly, the novel form of MAGI3 results from translation of a product of premature cleavage and polyadenylation (pPA) of the transcript at a cryptic intronic poly(A) signal. The truncated form of MAGI3 acts as a dominant-negative to inhibit a newly-discovered function of MAGI3 as an inhibitor of YAP. The paper is interesting both for this example of the role of pPA in cancer and for the new insights into YAP regulation. However, the reviewers have raised several major concerns. Substantial new data will be needed to address the reviewers\' comments. Since the new data will mostly come from further in-depth analysis of sequencing data, together with a few new experiments, we are offering you the opportunity to modify the paper and resubmit. However, if you cannot provide the data within the two months we normally allow for return of a revised submission, you should write back to indicate how you plan to proceed and indicate the length of time you expect it would take to comply with the required additional work. Alternatively, we understand that you may feel it is not possible to comply in which case you may choose to withdraw and submit this work elsewhere.

Essential revisions:

1\) The cause of the pPA event in MAGI3 is unknown, and may be due to a cis-acting mutation within the *MAGI3* gene or to a broad effect on many genes. The authors emphasize that the pPA is not due to mutation. To address this: (a) the entire *MAGI3* gene, not just the exons, must be sequenced; (b) the data from MDA-MB-231 cells and other cells with pPA of *MAGI3*, as well as some pPA-negative lines (e.g. MCF10A), should be mined for the occurrence of pPA events in other genes; and (c) the RNASeq data needs to be presented more clearly, statistical methods explained, and the relative abundance of RNA and protein isoforms in normal and cancer cells determined.

2\) The prevalence of pPA of *MAGI3* in breast cancer is unclear. Analysis of TCGA data or other published data sets is required.

3\) The literature on pPA in cancer should be discussed.

The comments of each reviewer are provided below for your information. The major comments have been distilled into the above essential revisions.

*Reviewer \#1:*

1\) It should be possible to access more RNASeq data to get better statistics on the frequency of tumors in which magi3 RNA is truncated.

2\) Better data on YAP subcellular localization should be provided.

3\) The authors should discuss previous evidence for premature cleavage/polyadenylation in cancer in more depth. In addition to the Mayr and Bartel 2009 paper, other seminal papers are Sandberg et al. 2008 Science 320:1643 and Singh et al. 2009 Cancer Res 69:9422. Previous examples of dominant negatives arising through transcript truncation include Yao et al. 2012 Cell 149:88 and Vorlova et al. 2011 Mol Cell 43:927.

*Reviewer \#2:*

1\) The authors strongly emphasize that they searched for abnormal proteins that were /not/ the result of genetic changes. However, it is unclear whether they have, in fact, ruled out the possibility that intronic mutations are responsible for the truncated MAGI3 isoform. They state: \"We sequenced MAGI3 but found no mutations in coding regions or exon-flanking intron sequences, indicating that this truncation was not generated by DNA mutation.\"

However, as far as I can tell, that they didn\'t sequence the entire intron containing the cryptic poly(A) site. Therefore, they can\'t conclude that local intronic mutations aren\'t responsible for the observed truncation. (Conversely, it\'s formally possible that a trans-acting cleavage or poly(A) factor could also be mutated. This possibility is difficult to rule out.) The bottom line is that the authors should not claim so strongly that they are studying unusual proteins that don\'t result from mutations.

2\) The analyses illustrated in [Figure 2](#fig2){ref-type="fig"} are neither well-described nor statistically robust. It\'s unclear whether the data shown in [Figure 2](#fig2){ref-type="fig"} is normalized w.r.t. total read coverage, which is an obvious potential confounding factor. Normalized read coverage plots are the relevant visual illustration. More importantly, the statistical thresholds that the authors used are insufficiently described. The description in \"Bioinformatic Analysis of RNA-Seq Data\" is not detailed enough to assess whether the authors are correctly distinguishing between premature polyadenylation and intron retention, etc. For this kind of analysis -- where they\'re comparing occurrence of an unusual isoform between primary cancers and peritumoral normal -- using a robust statistical procedure is essential.

3\) The authors need to clearly measure and describe the relative quantitative levels of the truncated vs. full-length isoforms of MAGI3. For example, the authors should have a single Western blot against MAGI3 showing their positive (MDA-MB-231) as well as negative (MCF10A, HMEC) samples (currently in [Figure 1C-D](#fig1){ref-type="fig"}). Similarly, the authors should quantitatively measure relative expression levels of the truncated isoform in their analyses of primary samples (see comment \#2 above). Quantitative comparisons are important because it\'s relatively rare for an aberrant isoform to be completely absent from normal cells, but highly expressed in cancer cells. Quantitative differences are much more common.

4\) The authors overemphasize the novelty of their results. For example, they state in the Abstract that: \"Our results suggest that pPA, by generating truncated and oncogenic mRNA isoforms, contributes to cancer as a previously overlooked mechanism of alteration.\"

Similarly, they state in the Discussion that: \"Premature cleavage and polyadenylation has not previously been known to alter genes in cancer.\"

However, alternative polyadenylation, including premature polyadenylation, has been extensively studied in the literature. For example, gene-proximal poly(A) sites are preferentially used in cancers (e.g., Sandberg et al., Science, 2008). Other authors have also studied truncated isoforms of specific cancer-relevant genes (e.g., Wiestner et al., Blood, 2007). Unusual isoforms generated by alternative splicing and premature polyadenylation have been particularly well-studied in the context of ligand-independent isoforms of the androgen receptor (e.g., Antonarakis et al., NEJM, 2014).

*Reviewer \#3:*

1\) The authors used 3\' RACE to implicate premature polyadenylation of MAGI3 in just one breast cancer cell line (MDA-MB-231). It would be more convincing if the same analysis can be done in the three primary tumors which the authors believe have similar aberration based on RNA-seq. This will exclude the possibility that the premature polyadenylation is something that happens during in vitro culture of cancer cell lines.

2\) The RNA-seq data in [Figure 2](#fig2){ref-type="fig"} is incomplete. It does not show coverage after the cryptic polyadenylation site. It is important to show coverage through the whole *MAGI3* gene, including all exons and introns, especially the ones after the cryptic polyadenylation site.

3\) The study left open the question of how such premature polyadenylation happens. Although the underlying molecular mechanisms may be the subject of a future study), it might be informative to analyze the RNA-seq data at whole genome level for the three primary tumors to determine whether premature polyadenylation happens in other genes. At least this will tell us whether this is a local or genome-wide phenomenon.

4\) In [Figure 6F](#fig6){ref-type="fig"}, the authors showed xenografts of MDA-MB-231 cells expressing full-length MAGI3. The expression level of MAGI3 full-length vs. truncated form should be examined to show their stoichiometry.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"Premature Polyadenylation of MAGI3 Produces a Novel Driver of Human Breast Cancer\" for further consideration at *eLife*. Your article has been favorably evaluated by Sean Morrison (Senior Editor) and three reviewers, one of whom is a member of our Board of Reviewing Editors.

The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:

1\) The authors need to clarify whether the RNA-seq data that they analyze in [Figure 2](#fig2){ref-type="fig"} is controlled for sequencing depth and expression of the *MAGI3* gene. If MAGI3 is much more highly expressed in cancer than in peritumoral normal cells, then they will a priori be much more likely to detect rare premature polyadenylation in the tumors than in the normals. This concern was raised in the previous review.

2\) The authors still overstate the novelty of their results in the Abstract, where they state: \"Here we report a new mechanism also capable of altering gene products to produce cancer drivers.\" This is incongruous with their Discussion, which places their work in the broader context of the field more appropriately. The discovery of premature polyadenylation in cancer is not new. The novelty is in the specific molecular mechanism of YAP regulation, not in pPA. The title is also too strong. Stating that a gene product is a \"driver\" of cancer typically means that it is sufficient transform cells in vivo, which the authors have not shown. One solution may be to substitute \"dominantly-acting oncogene\" for \"driver\" in the title, and replace the second sentence of the abstract with \"Here we report a new mechanism by which premature polyadenylation can produce an oncogenic protein.\"

10.7554/eLife.14730.025

Author response

Essential revisions:

1\) The cause of the pPA event in MAGI3 is unknown, and may be due to a cis-acting mutation within the MAGI3 gene or to a broad effect on many genes. The authors emphasize that the pPA is not due to mutation. To address this: (a) the entire MAGI3 gene, not just the exons, must be sequenced; (b) the data from MDA-MB-231 cells and other cells with pPA of MAGI3, as well as some pPA-negative lines (e.g. MCF10A), should be mined for the occurrence of pPA events in other genes; and (c) the RNASeq data needs to be presented more clearly, statistical methods explained, and the relative abundance of RNA and protein isoforms in normal and cancer cells determined.

2\) The prevalence of pPA of MAGI3 in breast cancer is unclear. Analysis of TCGA data or other published data sets is required.

3\) The literature on pPA in cancer should be discussed.

The comments of each reviewer are provided below for your information. The major comments have been distilled into the above essential revisions.

Reviewer \#1:

1\) It should be possible to access more RNASeq data to get better statistics on the frequency of tumors in which magi3 RNA is truncated.

We thank the reviewers for these suggestions and have performed analysis on the full set of paired breast tumor-normal RNA-Seq data from TCGA. This analysis shows a clear picture of *MAGI3^pPA^* in breast cancer ([Figure 2A-D](#fig2){ref-type="fig"}). Overall, 12 out of 160 (7.5%) tumors show evidence of pPA truncation of MAGI3 at intron 10 ([Figure 2C](#fig2){ref-type="fig"}). By contrast, intronic reads in MAGI3 intron 10 from peritumoral normal samples were limited to mostly rare events ([Figure 2A-B](#fig2){ref-type="fig"}), and none of these samples showed any evidence of *MAGI3^pPA^* ([Figure 2C](#fig2){ref-type="fig"}). These findings in the larger TCGA dataset are consistent with the frequency reported in our original manuscript (6%) that was based on a smaller non-TCGA dataset.

In light of these significant findings for tumor-recurring premature polyadenylation of MAGI3 in TCGA data, we felt that the importance of the pPA isoform -- as a novel driver isoform of breast cancer -- should be conveyed by the title of the paper. As such, we have revised the title of the manuscript to reflect this (now entitled "Premature Polyadenylation of MAGI3 Produces a Novel Driver of Human Breast Cancer").

2\) Better data on YAP subcellular localization should be provided.

We have provided better YAP subcellular localization images in [Figure 5C](#fig5){ref-type="fig"}.

3\) The authors should discuss previous evidence for premature cleavage/polyadenylation in cancer in more depth. In addition to the Mayr and Bartel 2009 paper, other seminal papers are Sandberg et al. 2008 Science 320:1643 and Singh et al. 2009 Cancer Res 69:9422. Previous examples of dominant negatives arising through transcript truncation include Yao et al. 2012 Cell 149:88 and Vorlova et al. 2011 Mol Cell 43:927.

We thank the reviewers for pointing out these omissions. In the revised Discussion section of the manuscript we discuss in greater depth the previous evidence for alternative 3' UTR polyadenylation in cancer and previous examples for dominant-negative proteins arising from pPA truncation (entitled "Premature Cleavage and Polyadenylation as a Cancer-Relevant Alteration Mechanism").

Reviewer \#2:

1\) The authors strongly emphasize that they searched for abnormal proteins that were /not/ the result of genetic changes. However, it is unclear whether they have, in fact, ruled out the possibility that intronic mutations are responsible for the truncated MAGI3 isoform. They state: \"We sequenced MAGI3 but found no mutations in coding regions or exon-flanking intron sequences, indicating that this truncation was not generated by DNA mutation.\"

However, as far as I can tell, that they didn\'t sequence the entire intron containing the cryptic poly(A) site. Therefore, they can\'t conclude that local intronic mutations aren\'t responsible for the observed truncation. (Conversely, it\'s formally possible that a trans-acting cleavage or poly(A) factor could also be mutated. This possibility is difficult to rule out.) The bottom line is that the authors should not claim so strongly that they are studying unusual proteins that don\'t result from mutations.

We appreciate the reviewers' comments and agree that it is important to rule out the presence of local intron 10 mutations in MAGI3. Because the *MAGI3* gene is extremely large (\~300 kb), we hope that the reviewers will agree with us that sequencing its entirety would be quite costly and provide little further value in interpreting the results. However, to address this important issue more directly, we have now sequenced the entire intron 10 of MAGI3 and found no mutations. In addition, we have sequenced the entire intron 10 region, along with the preceding exon 10, present in the MAGI3 pPA product isolated by 3' RACE. This also uncovered no mutations. Both analyses confirm that the major cis-acting sequence features known to dictate proper splicing and repression of cryptic intronic polyadenylation (5'/3' splice sites, upstream U1 snRNA binding sites, downstream U-rich elements) are not mutated. These data have been added to the Results section and [Figure 1---figure supplements 1](#fig1s1){ref-type="fig"} and [2](#fig1s2){ref-type="fig"}.

We also agree that is difficult to rule out the presence of mutations in trans-acting cleavage and polyadenylation factors. Likewise, while we have sequenced all 22 exons of MAGI3 and found no mutations, it would be difficult to rule out (or interpret the significance of) long-range, non-coding mutations elsewhere in the very large 300-kb *MAGI3* gene locus. Thus, we have revised our statements regarding the absence of mutations to indicate the absence of mutations in the local exonic and intronic regions surrounding the cryptic PAS in intron 10, since these are supported by our findings.

As the reviewer suggested, we also discuss the possibility of mutation/alteration to a trans-acting cleavage and polyadenylation factor in the revised Discussion section.

2\) The analyses illustrated in [Figure 2](#fig2){ref-type="fig"} are neither well-described nor statistically robust. It\'s unclear whether the data shown in [Figure 2](#fig2){ref-type="fig"} is normalized w.r.t. total read coverage, which is an obvious potential confounding factor. Normalized read coverage plots are the relevant visual illustration. More importantly, the statistical thresholds that the authors used are insufficiently described. The description in \"Bioinformatic Analysis of RNA-Seq Data\" is not detailed enough to assess whether the authors are correctly distinguishing between premature polyadenylation and intron retention, etc. For this kind of analysis -- where they\'re comparing occurrence of an unusual isoform between primary cancers and peritumoral normal -- using a robust statistical procedure is essential.

3\) The authors need to clearly measure and describe the relative quantitative levels of the truncated vs. full-length isoforms of MAGI3. For example, the authors should have a single Western blot against MAGI3 showing their positive (MDA-MB-231) as well as negative (MCF10A, HMEC) samples (currently in [Figure 1C-D](#fig1){ref-type="fig"}). Similarly, the authors should quantitatively measure relative expression levels of the truncated isoform in their analyses of primary samples (see comment \#2 above). Quantitative comparisons are important because it\'s relatively rare for an aberrant isoform to be completely absent from normal cells, but highly expressed in cancer cells. Quantitative differences are much more common.

We appreciate the comments and suggestions for the RNA-Seq analysis. We have revised the text to provide detailed descriptions of the RNA-Seq analysis scripts/tools, statistical methods, and thresholds used (Results section 2 and Materials and methods). To further improve overall clarity, we have also added visual depictions of our analyses ([Figure 2A](#fig2){ref-type="fig"}) and included a running tally of tumor and matched normal samples at each level of analysis ([Figure 2A](#fig2){ref-type="fig"}). As suggested, we also provide read coverage plots for the entire intron 10 of MAGI3, including the region after the cryptic PAS, for tumor-normal pairs ([Figure 2B](#fig2){ref-type="fig"}).

We thank the reviewers for their suggestions to quantify the stoichiometry/relative expression levels of FL isoforms versus the pPA isoform. Throughout the revision, we provide measurements for the relative expression of the pPA-truncated MAGI3 isoform versus the FL isoforms.

[Figure 2D](#fig2){ref-type="fig"}: For all 12 primary tumors identified by RNA-Seq analysis to express the pPA isoform of MAGI3, we have quantified the expression levels relative to both full-length MAGI3 isoforms.

[Figure 3B](#fig3){ref-type="fig"}: We quantify the levels of full-length versus pPA-truncated protein isoforms of MAGI3 in our control and knockdown experiments.

[Figure 6G](#fig6){ref-type="fig"}: For the tumor xenografts, we use qPCR to quantitatively determine the stoichiometry of FL:pPA MAGI3.

[Figure 1C](#fig1){ref-type="fig"}: As suggested, we performed a single Western blot against MAGI3 for MDA-MB-231 as well as normal (MCF10A and HMEC) samples. We were unable to detect the pPA-truncated MAGI3 in whole cell lysates obtained from normal cell lines (MCF10A, HMEC), even with longer exposures and higher total protein loaded for these samples compared to MDA-MB-231 cells. We have thus reproduced our original results, reaffirming our conclusion that the pPA truncation is not expressed in the normal mammary cell lines.

4\) The authors overemphasize the novelty of their results. For example, they state in the Abstract that: \"Our results suggest that pPA, by generating truncated and oncogenic mRNA isoforms, contributes to cancer as a previously overlooked mechanism of alteration.\"

Similarly, they state in the Discussion that: \"Premature cleavage and polyadenylation has not previously been known to alter genes in cancer.\"

*However, alternative polyadenylation, including premature polyadenylation, has been extensively studied in the literature. For example, gene-proximal poly(A) sites are preferentially used in cancers (e.g., Sandberg et al., Science, 2008). Other authors have also studied truncated isoforms of specific cancer-relevant genes (e.g., Wiestner et al., Blood, 2007). Unusual isoforms generated by alternative splicing and premature polyadenylation have been particularly well-studied in the context of ligand-independent isoforms of the androgen receptor (e.g., Antonarakis et al., NEJM, 2014).*

Please see response to Reviewer 1, point 3.

Reviewer \#3:

1\) The authors used 3\' RACE to implicate premature polyadenylation of MAGI3 in just one breast cancer cell line (MDA-MB-231). It would be more convincing if the same analysis can be done in the three primary tumors which the authors believe have similar aberration based on RNA-seq. This will exclude the possibility that the premature polyadenylation is something that happens during in vitro culture of cancer cell lines.

We agree that this would be a useful analysis, but it requires unavailable raw material from primary tumors. In addition, given the genetic heterogeneity of tumors and the complexity of tumor subtype in breast cancer, analysis of any random 3 primary tumors may not actually be that informative. Thus, to address this issue, we analyzed a larger, paired tumor-normal dataset from TCGA (that consists of \>100 primary tumors) and identified additional patient breast cancers that express *MAGI3^pPA^*. Also, we probed multiple breast cancer cell lines for MAGI3 truncation ([Figure 1B](#fig1){ref-type="fig"}), and the pPA truncation of MAGI3 does not appear to be a frequent event in cultured cancer cell lines suggesting this is not an artifact of ex vivo adaptation.

2\) The RNA-seq data in [Figure 2](#fig2){ref-type="fig"} is incomplete. It does not show coverage after the cryptic polyadenylation site. It is important to show coverage through the whole MAGI3 gene, including all exons and introns, especially the ones after the cryptic polyadenylation site.

Please see response to Reviewer 2, points 2 and 3.

3\) The study left open the question of how such premature polyadenylation happens. Although the underlying molecular mechanisms may be the subject of a future study), it might be informative to analyze the RNA-seq data at whole genome level for the three primary tumors to determine whether premature polyadenylation happens in other genes. At least this will tell us whether this is a local or genome-wide phenomenon.

We agree with the reviewers that determining the nature of premature polyadenylation in cancer -- as a focal or transcriptome-wide phenomenon -- is important. However, bioinformatics methods for identifying novel pPA events on a transcriptome-wide scale are currently lacking. In addition, methodology-building studies similar in scale to the proposed study represent major works in their own right (such as Vaquero-Garcia et al., e*Life*, 2016, and Xia et al., Nat. Commun., 2014). Thus, examining other genes for premature polyadenylation will have to await the development of pPA-finding computational methods, which we are currently working towards and is beyond the scope of this paper.

However, in this revised manuscript we focused our efforts on (1) improving our RNA-Seq analyses for identifying the *MAGI3^pPA^* event, and (2) ascertaining the frequency of pPA truncation of MAGI3 in a larger dataset of tumor-normal paired breast cancers from TCGA. In addition, given the importance of these findings, in the revised manuscript we devote a lengthy discussion of the potential impact of studying pPA events in cancer.

References:

Vaquero-Garcia et al. (2016). A new view of transcriptome complexity and regulation through the lens of local splicing variations. *eLife* 5, e11752.

Xia et al. (2014). Dynamic analyses of alternative polyadenylation from RNA-Seq reveal a 3'-UTR landscape across seven tumour types. Nat. Commun. 5, 5274.

4\) In [Figure 6F](#fig6){ref-type="fig"}, the authors showed xenografts of MDA-MB-231 cells expressing full-length MAGI3. The expression level of MAGI3 full-length vs. truncated form should be examined to show their stoichiometry.

Please see response to Reviewer 2, points 2 and 3.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:

1\) The authors need to clarify whether the RNA-seq data that they analyze in [Figure 2](#fig2){ref-type="fig"} is controlled for sequencing depth and expression of the MAGI3 gene. If MAGI3 is much more highly expressed in cancer than in peritumoral normal cells, then they will a priori be much more likely to detect rare premature polyadenylation in the tumors than in the normals. This concern was raised in the previous review.

We apologize for this omission. We compared upper quartile-normalized TPM or FPKM values for MAGI3 between tumor and tumor-adjacent normal tissues. The relative *MAGI3* expression is only slightly higher in tumors versus adjacent normal tissues (median \~ 1.1-fold increase), and this modest increase in sequencing depth of MAGI3 in tumor samples is unlikely to bias detection of premature polyadenylation of MAGI3. The methods and results are now reported in the manuscript.

*2) The authors still overstate the novelty of their results in the Abstract, where they state: \"Here we report a new mechanism also capable of altering gene products to produce cancer drivers.\" This is incongruous with their Discussion, which places their work in the broader context of the field more appropriately. The discovery of premature polyadenylation in cancer is not new. The novelty is in the specific molecular mechanism of YAP regulation, not in pPA. The title is also too strong. Stating that a gene product is a \"driver\" of cancer typically means that it is sufficient transform cells in vivo, which the authors have not shown. One solution may be to substitute \"dominantly-acting oncogene\" for \"driver\" in the title, and replace the second sentence of the abstract with \"Here we report a new mechanism by which premature polyadenylation can produce an oncogenic protein.\"*

Thank you for the helpful suggestions. We have made these changes to the title and Abstract of the manuscript.
